NCT03002025View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injection of JNJ-64304500 in Healthy Japanese and Caucasian Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 10, 2017

Primary Completion Date

September 9, 2017

Study Completion Date

September 9, 2017

Conditions
Healthy
Interventions
DRUG

JNJ-64304500

Participants will receive JNJ-64304500 as SC injection.

DRUG

Placebo

Participants will receive matching placebo to JNJ-64304500 as SC injection.

Trial Locations (1)

Unknown

Tokyo

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY